Melanin concentrating hormone receptor-1 antagonists

Details Melanin concentrating hormone receptor-1 antagonists Melanin concentrating hormone receptor-1 antagonists

2011-06-07

2011-06-07

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S249000, C514S413000, C514S422000, C544S349000, C548S453000, C548S466000, C548S518000

Reexamination Certificate

active

07956049

ABSTRACT:
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula Iwherein R1a, R1b, R1c, Q, A, R3, W, D and R2are defined herein.Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5698527 (1997-12-01), Kim
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5990145 (1999-11-01), Wehner et al.
patent: 6011045 (2000-01-01), Wehner et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6482821 (2002-11-01), Wehner et al.
patent: 2007/0093509 (2007-04-01), Washburn et al.
patent: 196 22 222 (1997-12-01), None
patent: 0 142 146 (1985-05-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 531 883 (1993-03-01), None
patent: 0 675 714 (1995-10-01), None
patent: 0 818 448 (1998-01-01), None
patent: 0 992 496 (2000-04-01), None
patent: 1 022 272 (2000-07-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2 304 106 (1997-03-01), None
patent: 54-32794 (1979-10-01), None
patent: 04 297478 (1992-10-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 95/15954 (1995-06-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 98/49899 (1998-11-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 00/73288 (2000-12-01), None
patent: WO 02/10146 (2002-02-01), None
patent: WO 02/101146 (2002-12-01), None
patent: WO 03/033476 (2003-04-01), None
patent: WO 03/035624 (2003-05-01), None
patent: WO 2004/058762 (2004-07-01), None
patent: WO 2004/092181 (2004-10-01), None
patent: WO 2005/042541 (2005-05-01), None
patent: WO2005/085221 (2005-09-01), None
patent: WO 2005/105805 (2005-11-01), None
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (on p. 3), 2001.
Carpenter, A. J. et al, “Melanin-concentrating hormone receptor antagonists as potential antiobesity agents”, Expert Opinion on Therapeutic Patents, vol. 12, No. 11, pp. 1639-1646 (2002).
Chemical Abstracts, Database accession No. 1973:84249, “Pyrrole-1,2-dicarboxyimides”.
Database WPI Week 200525, Derwent Publications Ltd., London, GB; AN 2005-242113: WO 2005/023782 A1 (Sankyo Co. Ltd.), Mar. 17, 2005, p. 95, compounds 9-138 (abstract).
Arnold, Z. et al., “Synthetic Reactions of Dimethylformamide. XXVII. A Simple Synthesis of Aminomalonaldehyde Derivatives”, Collection Czechoslov. Chem. Commun., vol. 38, pp. 2633-2640 (1973).
Beccalli, E.M. et al., “Pd-catalyzed intramolecular cyclization of pyrrolo-2-carboxamides: regiodivergent routes to pyrrolo-pyrazines and pyrrolo-pyridines”, Tetrahedron, vol. 61, pp. 1077-1082 (2005).
Bergman, J. et al., “Synthesis of IndolesviaRing Closure of 2-Alkylnitroaniline Derivatives”, Tetrahedron, vol. 46, No. 17, pp. 6085-6112 (1990).
Berlin, A. et al., “3-Alkylthiopyrroles: Synthesis and Oxidative Polymerization to Conductive Materials”, J. Chem. Soc. Perkin Trans. 2, pp. 699-704 (1990).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Boatman, R.J. et al., “Some Novel Reactions of Pyrrolecarboxylic Acid Chlorides”, J. Org. Chem., vol. 41, No. 18, pp. 3050-3051 (1976).
Borowsky, B. et al., “Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist”, Nature Medicine, vol. 8, No. 8, pp. 825-830 (2002).
Brimble, M.A. et al., “Synthesis of 2-Methylpyrrolo[1,2-a]pyrazin-1(2H)-one”, Aust. J. Chem., vol. 41, pp. 1583-1590 (1988).
Budhram, R.S. et al., “13C NMR Spectra of 2,3-Dihydro-1H-pyrrolo[1,2-c]imidazol-1,3-dione and its Thione Analogues”, Organic Magnetic Resonance, vol. 13, No. 2, pp. 89-91 (1980).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Carpenter, A.J. et al., “Novel benzimidazole-based MCH R1 antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 16, pp. 4994-5000 (2006).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, Journal of the American Chemical Society, vol. 98, No. 5, pp. 1291-1293 (1976).
Focella, A. et al., “The Synthesis of Two Phenacetin Metabolites”, Canadian Journal of Chemistry, vol. 50, pp. 2025-2030 (1972).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16, No. 1, pp. 16-30 (1998).
Gupton, J.T. et al., “Application of 2-Substituted Vinamidinium Salts to the Synthesis of 2,4-Disubstituted Pyrroles”, J. Org. Chem., vol. 55, No. 15, pp. 4735-4740 (1990).
Handy, S.T. et al., “An unusual dehalogenation in the Suzuki coupling of 4-bromopyrrole-2-carboxylates”, Tetrahedron Letters, vol. 44, pp. 427-430 (2003).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24, No. 4, pp. 425-430 (1999).
Hertzog, D.L. et al., “The discovery and optimization o

Affiliated with

Also associated with

Rating

Melanin concentrating hormone receptor-1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanin concentrating hormone receptor-1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanin concentrating hormone receptor-1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2639529